帕利哌酮缓释片治疗儿童青少年精神分裂症临床研究

A clinical study of paliperidone extended-release tablets in the treatment of child and adolescent schizophrenia

目的：探讨帕利哌酮缓释片治疗儿童青少年精神分裂症患者的疗效和安全性。方法对20例儿童青少年精神分裂症患者予以帕利哌酮缓释片治疗，观察8周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果本组患者治疗后阳性与阴性症状量表总分及各因子分较治疗前显著下降（ P＜0.05或0.01），治疗8周末显效率为45.0％，总有效率为70.0％；不良反应发生率低，程度较轻，主要表现为失眠、静坐不能、心动过速等。结论帕利哌酮缓释片治疗儿童青少年精神分裂症患者疗效显著，起效快，安全性高。

Objective To explore the efficacy and safety of paliperidone extended release tablets in the treatment of child and adolescent schizophrenia .Methods Twenty child and adolescent schizophrenics were treated with paliperidone extended release tablets for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results After treatment their total and each factor score of the PANSS lowered more significantly compared with pre‐treatment （P〈0.05 or 0.01） ,at the end of the 8th week obvious and total effective rate was respectively 45.0% and 70.0% ;the incidence of adverse reactions was low ,adverse reactions were mild and mainly in‐somnia ,akathisia ,tachycardia and so on .Conclusion Paliperidone extended release tablets have an evi‐dent effect ,take effect rapidly ,and safety is high .